95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes.
What does it actually take to deliver a pharmaceutical facility project without it going off the rails? This week, Thomas McMann sat down with someone who has spent over 30 years doing exactly that, from both sides of the table.
This week on Making It In Manufacturing, Thomas McMann sat down with Bruce Klopfenstein, Project Manager at GSK, with over 30 years of experience spanning project management, engineering, validation, EPC consulting, and client-side leadership across companies including GSK, Jacobs, JohnsonAndJohnson, Fujifilm and IBM.
In this episode, Bruce covers:
- Why getting ACV engaged at the very start of a project changes everything, and why the industry has been slow to do it.
- Who is actually responsible when a pharmaceutical project goes over budget, and why change control is almost always at the root of it.
- The $100,000 mistake that came down to a missing piece of paper, and the engineer who had to fly to Europe during Covid to fix it.
- How GSK is leading a major sustainability push through its low-carbon inhaler propellant project in France, and why 49% of their total annual emissions trace back to a single product type.
- Why AI adoption in pharmaceutical validation is no longer optional, and how companies like GSK and Eli Lilly are already using it inside the firewall, with Bruce's take on ValKit AI and what large language models can do for protocol generation at scale.
This is a genuinely experienced perspective on what it takes to manage complex pharmaceutical projects, and what the industry needs to do differently. Worth your time whether you are on the EPC side, the client side, or deep in the validation world.
Follow ARTO
LinkedIn: https://www.linkedin.com/company/artotalent
Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng
Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr
TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1
Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575
Website: https://arto-talent.com/
Youtube: https://www.youtube.com/@artotalent
Bruce Klopfenstein
LinkedIn: https://www.linkedin.com/in/bruceklopfenstein/
Thomas McMann
LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/
Timestamps:
0:00 Introduction
1:40 Bruce's ISP talk: early ACV engagement from Basis of Design through Detailed Design
3:13 Bruce's career journey: IBM, PricewaterhouseCoopers, gaming industry, J&J, and life science
8:09 Finding the most enjoyable moments: it is about the team and the situation, not just the job
13:13 Engineering complexity of the 152A propellant transition and where the project currently stands
16:33 The CO2 comparison between pharma and automotive: why the headline is misleading
19:54 Who is responsible when a project goes over budget? EPC vs client-side accountability
23:08 The biggest differences between working on the EPC side vs the client side
25:20 Why relationships are the foundation of every successful project
30:10 EPC stress vs owner stress: where the real pressure sits
36:18 Why pharma struggles to standardise the way oil and gas has
40:04 Change control in practice: what it actually requires
43:07 Equipment lead times and Covid-era supply chain pressure on the critical path
45:44 AI in pharmaceutical validation: where the industry is today
46:26 ValKit AI and Hugh Devine: using LLMs to generate validation protocols
47:18 The FDA's first AI warning letter and what it means for human oversight
53:31 How to think about AI like a smart intern: natural language, not programming
55:38 Why companies that are not adopting AI now will fall behind
56:00 Closing thoughts and sign-off
#MakingItInManufacturing #ARTOTalent #ProjectManagement #Validation #LifeSciences #Biotech #AIInPharma #Commissioning #GMP #DrugManufacturing #Sustainability #GSK #EPC
","author_name":"ARTO Talent"}